Navigation Links
Oncolytics Biotech Inc. Announces 2008 Third Quarter Results
Date:11/4/2008

CALGARY, Nov. 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results for the three and nine-month periods ended September 30, 2008.

Recent Pivotal Trial Decision

Oncolytics made a decision in early November to pursue a pivotal (Phase II/III) randomized trial using the combination of REOLYSIN(R) with paclitaxel/carboplatin in refractory patients with head and neck cancers. The decision was made following a review of results by the Company's Board of Directors from the Company's ongoing U.K. Phase I and Phase II combination REOLYSIN(R) and paclitaxel/carboplatin clinical trials. The results were presented November 1, 2008 at the International Society for Biological Therapy of Cancer (iSBTc) annual meeting in San Diego, CA.

Selected Third Quarter Highlights:

- Treatment of the 200th patient in clinical studies with REOLYSIN(R);

- Completion of patient enrolment in the dose escalation portion of its

U.K. clinical trial to evaluate the anti-tumour effects of systemic

administration of REOLYSIN(R) in combination with docetaxel

(Taxotere(R)) in patients with advanced cancers including bladder,

prostate, lung and upper gastro-intestinal;

- The U.S. National Cancer Institute (NCI), part of the National

Institutes of Health, started enrolment in a Phase II clinical trial

for patients with metastatic melanoma using systemic administration

of REOLYSIN(R);

- The start of patient enrolment in a U.S. Phase II clinical trial

using intravenous administration of REOLYSIN(R) in combination with

paclitaxel and carboplatin in patients with advanced head and neck

cancers;

- Initiation of a U.S. Phase II clinical trial using intravenous

administration of REOLYSIN(R) in combination with paclitaxel and

carb
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... 21, 2014 Lawrence Livermore ... Board (WIB) and Las Positas College (LPC) recently ... education and hands-on training for veterans, officials recently ... at Las Positas is designed to help ... engineering technician careers, and establishes a pipeline of ...
(Date:7/21/2014)... July 21, 2014  Mike Patterson, CEO of ... million in Series Seed B funding to finance ... for the life science, defense, intelligence, and environmental ... led the round and was joined by R2M ... Said Patterson , "This round of funding will ...
(Date:7/19/2014)... 2014 United States Non-Vascular Stents ... new report, "United States Non-Vascular Stents Market Outlook ... United States Non-Vascular Stents market. The report provides ... units) and average prices (in US dollars) within ... and Metal Biliary Stents (Metal Non-Covered Biliary Stents, ...
(Date:7/18/2014)... Reflecting the importance of the evolution of Houston’s real estate ... founder and president of Customized Real Estate Services , ... approach to the firm’s branding. , According to Ms. ... of his or her commercial clients have grown exponentially over ... in this market to fully embrace the potential for helping ...
Breaking Biology Technology:Engineering Program Established for Veterans 2Engineering Program Established for Veterans 3Global Graphene Manufacturing Leader, Graphene Frontiers, Receives Series Seed B Funding To Assure Production Of The Next Generation Of Biological And Chemical Sensor Technology 2United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 2United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 3United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 4LEED AP Certified ITRA Global / Customized Real Estate Services Introduces New Approach to Its Branding 2
... Okla., April 14 Aaron,s Bridge presents Autism ... 13-14, 2009, at The Embassy Suites Hotel and ... The conference will feature seminars devoted to educating ... MD; Bryan Jepson, MD; Dan Rossignol, MD; and ...
... April 14 Bio-Optronics, Inc. and ... to cross-market and integrate Bio-Optronics, Clinical Conductor Clinical ... Data Capture (EDC) solution. This aligns the industry,s ... to provide clinical research with the best tools ...
... New Vice President of Healthcare Brings 22 Years ... April 14 Prolifiq Software, Inc., today announced ... as vice president of healthcare. In this role, ... email messaging services for sales representatives in the ...
Cached Biology Technology:Defeat Autism Now!(R) Regional Conference to be Held in Oklahoma June 13-14, 2009 2Bio-Optronics Adds Innovative Electronic Data Capture (EDC) Solution to Clinical Conductor Clinical Trial Management System (CTMS), Continues to Improve Workflow and Productivity 2Prolifiq Further Expands Into Medical Markets With New Hire Maureen A. Shaffer 2Prolifiq Further Expands Into Medical Markets With New Hire Maureen A. Shaffer 3
(Date:7/21/2014)... of California, San Diego School of Medicine-led study suggests ... the potentially serious health consequences of childhood weight gain ... their child reach a healthy weight. , The study ... Academy of Nutrition and Dietetics . , "Parents have ... activity behaviors," said lead author Kyung Rhee, MD, and ...
(Date:7/21/2014)... infectious diseases, vaccination, antibiotic resistance, and cheating in ... by leading bacteriology, virology, and mycology experts in ... Societies congresses (IUMS) from July 27 to August ... 80 countries are expected at the 14th International ... International Congress of Mycology and Eukaryotic Microbiology, and ...
(Date:7/21/2014)... 154 hotspots in areas across Riau province on Sunday, ... again following a decline in rainfall. The number ... than what had been reported one day prior, which ... scattered in six regencies and municipalities, most of which ... related haze it creates could potentially spread via winds ...
Breaking Biology News(10 mins):Parents rank their obese children as 'very healthy' 2Montreal hosts International Union of Microbiology Societies congresses 2
... optical images of diseased tissues. So, four years ago ... Now, Wilson, a professor of biomedical engineering at Case ... in preclinical imaging studies. And he can pinpoint exactly ... Called cryo-imaging, the system enables Wilson and collaborators ...
... a huge number of new species of invertebrate animals ... harsh conditions of the Australian outback. A national ... of invertebrates, which include various insects, small crustaceans, spiders, ... by Professor Andy Austin (University of Adelaide), Dr Steve ...
... at the University of Pittsburgh received two grants totaling ... Health (NIH) to explore new methods for cultivating replacement ... million, five-year Transformative R01 (T-R01) grant presented to Eric ... Medicine and a researcher in Pitt and UPMC,s jointly ...
Cached Biology News:Getting down to details 2Researchers go underground to reveal 850 new species 2Pitt researchers net $5 million from NIH to explore better ways to grow cells for regenerative medicine 2Pitt researchers net $5 million from NIH to explore better ways to grow cells for regenerative medicine 3
... The genus Salmonella is a member of ... Gram-negative bacilli that are facultative and flagellated (motile). ... flagellar antigen (phase 1 & 2), the "O" ... and the "Vi" or capsular antigen (referred to ...
... sequence: H-Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH 2 ... corresponding peptide and ... 5 I-labelled peptide, please ... and ([ 1 ...
This free-standing laminar flow hood provides a horizontal flow of HEPA-filtered air to create a clean processing area. Air return slots along the front and side edges of the work area enhance system...
...
Biology Products: